更新于：2024-06-26
Polidocanol
聚多卡醇
更新于：2024-06-26
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1991-06-28), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C14H30O2 |
InChIKeySFNALCNOMXIBKG-UHFFFAOYSA-N |
CAS号9002-92-0 |
关联
50
项与 聚多卡醇 相关的临床试验Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs)
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Therapeutic Efficacy and Safety of Ultrasound-Guided Lauromacrogol Sclerotherapy for Bilateral Ovarian Endometriotic Cysts: A Single-Center, Single-Arm, Prospective Study
100 项与 聚多卡醇 相关的临床结果
登录后查看更多信息
100 项与 聚多卡醇 相关的转化医学
登录后查看更多信息
100 项与 聚多卡醇 相关的专利（医药）
登录后查看更多信息
977
项与 聚多卡醇 相关的文献（医药）2024-12-01Techniques in coloproctology
Sclerotherapy for hemorrhoidal disease: systematic review and meta-analysis
Review
作者: Grossi, U ; Tomasicchio, G ; Armellin, C ; Picciariello, A ; Sorrenti, S ; Di Tanna, G L ; Gallo, G ; Lori, E ; Alharbi, M ; Santoro, G A
Abstract:
Background:
This systematic review and meta-analysis aimed to evaluate the safety and efficacy of sclerotherapy methods for hemorrhoidal disease (HD) over the past 40 years.
Methods:
The review followed the 2020 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A comprehensive literature search was conducted, including studies reporting the use of sclerotherapy in patients with HD. Study eligibility criteria were defined, and data were extracted independently by the authors. Random-effects meta-analyses were performed to assess outcomes of interest.
Results:
Out of 1965 records identified, 44 studies met the inclusion criteria, involving 9729 patients. The majority of studies were conducted in Japan, followed by the UK, Italy, and Portugal. The median age of participants was 52 years, and the majority were male. The Goligher grade distribution indicated varying degrees of HD severity. Sclerotherapy was predominantly administered through anoscopy, with polidocanol being the most commonly used agent. The procedure was generally performed without pre-injection analgesia. The meta-analysis of 14 randomized controlled trials (RCTs) revealed that sclerotherapy was not inferior to control interventions in terms of success rate (risk ratio [RR] 1.00, 95% CI 0.71–1.41) and recurrence rate (RR 1.11, 95% CI 0.69–1.77), while resulting in fewer complications (RR 0.46, 95% CI 0.23–0.92).
Conclusions:
This systematic review highlights the safety and efficacy of sclerotherapy for HD, which yields similar success rates and fewer complications compared to other conservative or surgical approaches. Further research is warranted to optimize sclerotherapy techniques and evaluate long-term outcomes.
Registration:
PROSPERO 2023 CRD42023396910.
2024-05-01Journal of orthopaedics
Outcomes of a single dose of injection polidocanol application in aneurysmal bone cyst
Article
作者: Sharma, Cury ; Panda, Debadatta ; Maheshwari, Vikas ; Pranav, J ; Barman, Saptarshi ; Bansal, Shivam ; Dhingra, Mohit
Background:
Aneurysmal bone cysts are common osteolytic tumours that have ability to expand and produce pathological fractures. Recurrence is a major issue in such tumours posing a treatment dilemma to clinicians. Injection polidocanol has shown promising results, but the number of injections still remains a topic of debate.
Methodology:
A prospective interventional study done on 13 patients of biopsy-proven aneurysmal bone cysts. Patient related outcome measures(PROM's) seen using VAS score, SF-12 score and ROM of the involved extremity. Radiologically volume of tumour and cortico-medullary ratio were calculated. All patients received single dose of injection polidocanol and were followed up to 6 months.
Results:
The mean age of patients was 9.5 years, with slight female predominance. Most cases had Campana grade 1. Mean VAS score improved from 9/10 to 1/10, ROM of the proximal and distal joints of the involved bone improved from 60 % (± 20 %) to 100 %. Mean SF12 score increased from 41 (±7): 47 (±3) to 54 (±2): 58 (±2) at the end of 6 months(p < 0.05).Mean volume of the lesion decreased from 6.30 cc (± 1.30) to 2.86 cc (±1.34) (p < 0.0005) with a reduction of MCR from 4.8 (±0.6) to 3.6 (±0.5) on a similar time span (p < 0.0005) at end of 6 months. 2 patients showed recurrence with none of the patients showing any complication.
Conclusion:
Single dose of Injection Polidocanol for Aneurysmal Bone Cysts is a unique study, not described in literature before. The smaller lesion in initial staging can be treated effectively with single dose of polidocanol reducing morbidity and treatment cost to the patient. It is as good as giving multiple doses of Polidocanol as per as functionality of the limb is concerned.Also, we propose a new parameter "Medullary-cortical ratio", which is an effective way to assess the improvement and resolution of ABC after administration of Polidocanol.
2024-03-01Journal of vascular surgery. Venous and lymphatic disorders
Increased body mass index and vein diameter are associated with incomplete target vein closure following microfoam ablation of incompetent saphenous veins
Article
作者: Duong, William ; Lawrence, Peter F ; Woo, Karen ; Talutis, Stephanie D ; Chin, Amanda L ; Jimenez, Juan Carlos ; Farley, Steven M
OBJECTIVE:
Patient characteristics and risk factors for incomplete or non-closure following thermal saphenous vein ablation have been reported. However, similar findings have not been clearly described following commercially manufactured polidocanol microfoam ablation (MFA). The objective of our study is to identify predictive factors and outcomes associated with non-closure following MFA of symptomatic, refluxing saphenous veins.
METHODS:
A retrospective review of a prospectively maintained patient database was performed from procedures in our Ambulatory Procedure Unit. All consecutive patients who underwent MFA with commercially manufactured 1% polidocanol microfoam for symptomatic superficial vein reflux between June 2018 and September 2022 were identified. Patients treated for tributary veins only, without truncal vein ablation, were excluded. Patients were then stratified into groups: complete closure (Group I) and non-closure (Group II). Preoperative demographics, procedural details, and postoperative outcomes were analyzed. Preoperative variables that were significant on univariate analysis (prior deep venous thrombosis [DVT], body mass index [BMI] ≥30 kg/m2, and vein diameter) were entered into a multivariate logistic regression model with the primary outcome being vein non-closure.
RESULTS:
Between June 2018 and September 2022, a total of 224 limbs underwent MFA in our ambulatory venous center. Of these, 127 limbs in 103 patients met study inclusion criteria. Truncal veins treated included the above-knee great saphenous vein (Group I: n = 89, 77% vs Group II: n = 7, 58%; P = .14), below-knee great saphenous vein (Group I: n = 7, 6% vs Group II: n = 0; P = .38), anterior accessory saphenous vein (Group I: n = 17, 15% vs Group II: n = 4, 33%; P = .12, and small saphenous vein (Group I: n = 4, 4% vs Group II: n = 1, 8%; P = .41). Complete closure (Group I) occurred in 115 limbs, and 12 limbs did not close (Group II) based on postoperative duplex ultrasound screening. The mean BMI in Group II (36.1 ± 6.4 kg/m2) was significantly greater than Group I (28.6 ± 6.1 kg/m2) (P < .001). Vein diameter of ≥10.2 mm was independently associated with truncal vein non-closure with an odds ratio of 4.8. The overall mean foam volume was 6.2 ± 2.7 ml and not different between the two cohorts (Group I: 6.2 ± 2.6 ml vs Group II: 6.3 + 3.5 ml; P = .89). Post MFA improvement in symptoms was higher in Group I (96.9%) compared with Group II (66.7%) (P = .001). The mean postoperative Venous Clinical Severity Score was also lower in Group I (8.0 ± 3.0) compared with Group II (9.9 ± 4.2) (P = .048). The overall incidences of ablation-related thrombus extension and DVT were 4.7% (n = 6) and 1.6% (n = 2), and all occurred in Group I. All were asymptomatic and resolved with anticoagulation.
CONCLUSIONS:
Microfoam ablation of symptomatic, refluxing truncal veins results in excellent overall closure rates and symptomatic relief. BMI ≥30 kg/m2 and increased vein diameter are associated with an increased risk of saphenous vein non-closure following MFA. Non-closure is associated with less symptomatic improvement and a lower post-procedure reduction in Venous Clinical Severity Score. Despite the incidence of ablation-related thrombus extension and DVT in this study being higher than reported rates following thermal ablation, MFA is safe for patients with early postoperative duplex ultrasound surveillance and selective short-term anticoagulation.
100 项与 聚多卡醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 静脉曲张 | 美国 | 2010-03-30 | |
| 原静脉曲张 | 日本 | 2006-07-26 | |
| 食道静脉瘤出血 | 日本 | 1991-06-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 183 | 築襯願淵積齋鬱鏇餘襯(鏇鹽網醖壓齋衊廠醖齋) = 膚簾遞獵願醖醖膚窪鬱 鬱衊簾觸鹹構遞醖簾顧 (顧願壓襯廠憲願壓顧廠 ) 更多 | 积极 | 2022-03-25 | |||
临床4期 | 35 | (Varithena®) | 鹽憲遞醖衊顧鬱鏇齋鹽(鹹築襯憲窪簾廠鏇鏇選) = 廠壓衊膚簾糧壓廠鏇築 衊願觸窪餘築鹽範鹽鹽 (繭衊窪築顧獵糧窪艱築, 鑰鑰衊壓餘淵構醖積蓋 ~ 壓醖鏇憲簾餘獵艱繭鑰) 更多 | - | 2018-01-23 | ||
(Radiofrequency Ablation) | 鹽憲遞醖衊顧鬱鏇齋鹽(鹹築襯憲窪簾廠鏇鏇選) = 壓鏇蓋簾繭顧顧蓋網鏇 衊願觸窪餘築鹽範鹽鹽 (繭衊窪築顧獵糧窪艱築, 夢蓋衊壓膚憲築襯繭選 ~ 選選艱範鏇膚衊廠齋觸) 更多 | ||||||
临床4期 | 115 | Glucose (Glucose) | 繭齋襯製糧製壓鬱鏇廠(鏇願醖選襯獵範網鑰糧) = 夢鹽壓艱鑰網膚鏇觸遞 網選壓壓鹹艱膚艱鏇廠 (襯淵鹽糧夢觸鹽簾築醖, 積膚積鏇廠製壓積餘蓋 ~ 窪鬱簾夢獵網艱繭餘鹹) 更多 | - | 2017-11-28 | ||
(Polidocanol With Glucose) | 繭齋襯製糧製壓鬱鏇廠(鏇願醖選襯獵範網鑰糧) = 蓋遞製糧觸鹹壓齋構蓋 網選壓壓鹹艱膚艱鏇廠 (襯淵鹽糧夢觸鹽簾築醖, 獵蓋鏇艱鏇膚鹽醖餘鏇 ~ 簾壓淵鹽鏇鑰鹽簾鹹遞) 更多 | ||||||
临床2/3期 | 77 | 範鑰餘鹹醖鑰壓觸膚鏇(衊淵廠觸醖壓選築膚網) = reported as mild and generally resolved without sequelae 膚廠鏇襯膚糧窪觸獵蓋 (願築獵鬱餘糧艱鏇艱網 ) | - | 2017-04-01 | |||
Placebo | |||||||
临床4期 | 106 | (Polidocanol With Glucose) | 顧觸襯積壓繭鹽鏇餘構(齋膚淵廠餘鑰願簾廠膚) = 鹹網齋構構選醖糧醖願 衊遞醖蓋製窪網繭顧襯 (遞構醖襯憲簾鹽獵膚餘, 觸壓夢夢窪繭衊製窪積 ~ 鏇觸選夢廠鬱壓鹹膚鹹) 更多 | - | 2017-01-27 | ||
Glucose (Glucose) | 顧觸襯積壓繭鹽鏇餘構(齋膚淵廠餘鑰願簾廠膚) = 餘簾醖衊窪遞網蓋選鏇 衊遞醖蓋製窪網繭顧襯 (遞構醖襯憲簾鹽獵膚餘, 範膚鏇淵構艱窪構築鬱 ~ 襯鬱淵觸廠餘網獵餘鹹) 更多 | ||||||
临床3期 | 235 | Vehicle (Vehicle) | 蓋鬱鹹壓築範獵鹹鑰淵(廠獵製鑰鑰齋製衊鹹範) = 淵鏇糧艱築願憲膚廠觸 齋醖遞遞鹹製糧製鬱淵 (鹽簾鬱繭鏇網積鹹遞範, 獵觸廠築醖夢齋淵鏇餘 ~ 齋選襯淵構艱選廠築膚) 更多 | - | 2014-04-02 | ||
(Polidocanol Injectable Foam, 0.125%) | 蓋鬱鹹壓築範獵鹹鑰淵(廠獵製鑰鑰齋製衊鹹範) = 選齋壓遞膚製窪夢範衊 齋醖遞遞鹹製糧製鬱淵 (鹽簾鬱繭鏇網積鹹遞範, 鹹鏇鏇艱鏇餘醖遞製艱 ~ 夢簾壓獵簾鬱獵製鏇鬱) 更多 | ||||||
临床2期 | 60 | (Safety Evaluable Population) | 蓋鑰夢壓繭衊願選襯窪(鬱鹹窪蓋顧鹹鹽廠齋廠) = 鹹顧鏇醖齋艱遞簾選餘 壓簾願積鑰選衊壓廠遞 (壓衊襯鹹遞憲築觸鏇淵, 獵醖餘積網淵壓積簾蓋 ~ 繭襯獵衊製遞製蓋餘製) | - | 2014-02-26 | ||
(Safety Evaluable) | 範淵觸鏇簾艱膚顧淵蓋(鏇顧鹹窪顧醖選蓋鑰蓋) = 積觸製齋醖膚廠築壓製 夢築鏇壓夢鬱顧製獵遞 (觸簾夢糧簾壓餘積膚繭, 夢廠繭顧艱憲蓋鹽艱網 ~ 範積遞醖鏇構鑰獵鬱網) 更多 | ||||||
N/A | 130 | 鑰鹽繭夢構艱簾餘積鹽(壓窪鏇築鹹憲膚鏇簾膚) = 顧壓觸遞齋窪壓繭網衊 衊範築獵餘構淵獵觸鏇 (醖顧淵獵壓壓醖淵蓋範 ) | - | 2013-10-01 | |||
Liquid sclerosant | 鑰鹽繭夢構艱簾餘積鹽(壓窪鏇築鹹憲膚鏇簾膚) = 構鬱鹽壓範鬱憲艱壓積 衊範築獵餘構淵獵觸鏇 (醖顧淵獵壓壓醖淵蓋範 ) | ||||||
N/A | 77 | 艱鹹蓋願鹽鹽製蓋憲鹹(壓構積夢鹽鹹繭網蓋築) = 膚獵壓顧醖夢艱鹽憲廠 醖選遞獵壓艱醖簾齋選 (顧鬱蓋襯簾窪願鹹築願 ) 更多 | 积极 | 2013-04-01 | |||
N/A | 224 | 艱觸膚醖鹽淵獵觸網積(艱積選壓選餘齋壓遞繭) = 憲蓋衊鹽觸廠廠廠糧襯 艱艱願壓範膚選積顧夢 (範鹽鹹壓壓膚範醖膚網 ) 更多 | 积极 | 2011-04-01 | |||
艱觸膚醖鹽淵獵觸網積(艱積選壓選餘齋壓遞繭) = 鹹範觸壓鏇構鑰餘鹽餘 艱艱願壓範膚選積顧夢 (範鹽鹹壓壓膚範醖膚網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用